课题基金 / 基金详情

Platelet-microparticles as a carrier of chemical mediators inducing remote organ failure

Platelet-microparticles as a carrier of chemical mediators inducing remote organ failure
血小板微粒作为化学介质的载体诱导远端器官衰竭
批准号:
12671155
负责人:
KAWASAKI tomio
金额:
$2.11万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2000
资助国家:
日本
项目状态:
已结题
起止时间:
2000 至 2002

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The chemical mediators are secreted from activated platelets. The mediators actually made a play on peripheral vessels and sometimes made remote organ failure even though those materials are instantaneously resolved in blood. We have identified that the microparticles (MP) released from activated platelets were a transporter of the chemical mediators. In order to clarify the release mechanism and physiological meaning of MP the following projects were performed. MP production, platelet P selectin expression, platelet-monocyte binding, and platelet-polymorphonuclear cell binding increased in number in systemic inflammatory syndrome. Anti-P-selectin antibody clearly inhibited platelets-polymorphonuclear cell aggregation. In addition, leukocyte-platelet interaction and endothelial-MP binding were increased in patients with septic condition. Moreover, when the biorheology of the whole blood from septic patients was analyzed with the microarray bloodstream analyzer, the stiffness of white blood cells was increased. The result indicated that migration of white blood cells through the vessel wall was thought to be impaired. The white blood cells, stiffened by inflammation, may be trapped in the local stasis lesion. The platelet and MP bonded to the white blood cells made a new bonding to the other white blood cells. As a result, quite a new mechanism was advocated that start of coagulation accumulates the chemical mediators in inflammatory lesion. Moreover, it was clarified that the cause of activated protein C resistance (APC-R) in venous thrombosis in our country was not due to factor V Leiden gene mutation as was reported in Europe and America. It is not antibodies to phospholipids but anti-protein S antibodies that express APC-R in Japan. And this is the first report in the world (British Journal of Haematology 2002, 118, 577-583,Thromb Haemost 2002, 88, 716-722).
期刊论文(25)
专著(0)
科研奖励(0)
会议论文
Ogasawara, N, Kijima, Y., Ike, S., Nakagawa, Y., Takagi, T, Hata, T.Suehisa, E., Kawasaki, T., Miyata, T.: "Hereditary protein S deficiency with a history of recurrent myocardial infarction. -A case report-"Circ. J.. 67・2. 166-168 (2003)
Ogasawara, N, Kijima, Y., Ike, S., Nakakawa, Y., Takagi, T, Hata, T.Suehisa, E., Kawasaki, T., Miyata, T.:“有历史的遗传性蛋白质 S 缺乏症-复发性心肌梗塞的病例报告-“Circ. J. 67・2. 166-168 (2003)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Fujimura H.: "Common C677T polymorphism in the methylenetetrahydrofolate reductase gene increases the risk for deep vein thrombosis in patients with predic position of thrombophilie"Thrombos Res. 98. 1-8 (2000)
Fujimura H.:“亚甲基四氢叶酸还原酶基因中常见的 C677T 多态性会增加具有易栓症预测位置的患者发生深静脉血栓的风险”Thrombos Res。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Nojima J., Kuratsune H, Suehisa E, Kawasaki T., Machii T., Kitani T., Iwatani Y., Kanakura Y.: "Acquired activated protein C resistance associated with anti-protein S antibody as a strong risk factor for DVT in non-SLE patients"Thromb. Haemost.. 88. 716-7
Nojima J.、Kuratsune H、Suehisa E、Kawasaki T.、Machii T.、Kitani T.、Iwatani Y.、Kanakura Y.:“与抗蛋白 S 抗体相关的获得性活化蛋白 C 抵抗是 DVT 的一个强烈危险因素
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Suehisa, E., Nomura, T., Kawasaki, T., Kanakura, Y.: "frequency of natural coagulation inhibitor (antithrombin III, Protein C and protein S) deficiencies in Japanese patients with spontaneous deep vein thrombosis."Blood Coagul Fibrinolysis. 12. 95-99 (200
Suehisa, E.、Nomura, T.、Kawasaki, T.、Kanakura, Y.:“日本自发性深静脉血栓形成患者中天然凝血抑制剂(抗凝血酶 III、蛋白 C 和蛋白 S)缺乏的频率。”血液凝固纤溶
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
24
    国内基金
    海外基金
    FLOT1-GCEVs通过GRP75诱导肝细胞线粒体功能障碍和PMN的形成促进胃癌肝转移的作用及机制研究
    • 批准号:
      2026JJ60297
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
      王然
    • 依托单位:
    PMN-MDSCs源性eNAMPT通过“ 唤醒”休眠肿瘤细胞诱导NSCLC化疗后复发的作用及机制研究
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
      张敏
    • 依托单位:
    基于PMN-MDSC内源性ITA介导PD-L1烷基化修饰探索IFN-γ干预在儿童脓毒症中的作用机制
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
      应佳云
    • 依托单位:
    基于“LDH 降解-外泌体抑制”克服乳腺癌化疗耐药及远端PMN 形成的药效及机制研究
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      20.0万元
    • 批准年份:
      2024
    • 负责人:
      钱妍
    • 依托单位: